Jonathan Miller
Stock Analyst at Evercore ISI Group
(0.03)
# 4,513
Out of 5,147 analysts
7
Total ratings
16.67%
Success rate
-32.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $14 → $19 | $13.27 | +43.18% | 1 | Feb 25, 2026 | |
| AURA Aura Biosciences | Reinstates: Outperform | $13 | $5.89 | +120.71% | 1 | Nov 26, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $13.78 | -41.94% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $2.24 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $11.93 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $3.92 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $31.04 | - | 1 | Jan 6, 2021 |
Arvinas
Feb 25, 2026
Maintains: Outperform
Price Target: $14 → $19
Current: $13.27
Upside: +43.18%
Aura Biosciences
Nov 26, 2025
Reinstates: Outperform
Price Target: $13
Current: $5.89
Upside: +120.71%
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $13.78
Upside: -41.94%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.24
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.93
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.92
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $31.04
Upside: -